CA2307079A1 - Compositions utiles pour le traitement de maladies du tissu conjonctif - Google Patents

Compositions utiles pour le traitement de maladies du tissu conjonctif Download PDF

Info

Publication number: CA2307079A1
Authority: CA; Canada
Prior art keywords: ascorbate; glucosamine; composition according; per day; ferrous
Prior art date: 2000-04-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2307079

Other languages

English (en)

Inventor

Sunetra Ekanayake

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Ocean Nutrition Canada Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-28

Filing date

2000-04-28

Publication date

2001-10-28

2000-04-28 Application filed by Ocean Nutrition Canada Ltd filed Critical Ocean Nutrition Canada Ltd

2000-04-28 Priority to CA 2307079 priority Critical patent/CA2307079A1/fr

2001-10-28 Publication of CA2307079A1 publication Critical patent/CA2307079A1/fr

Status Abandoned legal-status Critical Current

Links

241000607056 Stenodus leucichthys Species 0.000 title 1
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 189
235000010323 ascorbic acid Nutrition 0.000 claims abstract description 92
239000011668 ascorbic acid Substances 0.000 claims abstract description 92
239000000203 mixture Substances 0.000 claims abstract description 63
229960005070 ascorbic acid Drugs 0.000 claims abstract description 52
229940072107 ascorbate Drugs 0.000 claims abstract description 40
201000008482 osteoarthritis Diseases 0.000 claims abstract description 39
229910021645 metal ion Inorganic materials 0.000 claims abstract description 33
CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims abstract description 31
229910001448 ferrous ion Inorganic materials 0.000 claims abstract description 30
239000011790 ferrous sulphate Substances 0.000 claims abstract description 28
235000003891 ferrous sulphate Nutrition 0.000 claims abstract description 28
150000002301 glucosamine derivatives Chemical class 0.000 claims abstract description 28
CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 claims abstract description 15
229960001911 glucosamine hydrochloride Drugs 0.000 claims abstract description 15
201000010099 disease Diseases 0.000 claims description 23
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
238000000034 method Methods 0.000 claims description 16
208000018631 connective tissue disease Diseases 0.000 claims description 14
150000003839 salts Chemical class 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 5
239000003085 diluting agent Substances 0.000 claims description 4
239000000546 pharmaceutical excipient Substances 0.000 claims description 4
CAOFVLJHCHGTGE-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydroiodide Chemical compound I.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CAOFVLJHCHGTGE-BTVCFUMJSA-N 0.000 claims description 3
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 3
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 3
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 3
239000002775 capsule Substances 0.000 claims description 3
229950006780 n-acetylglucosamine Drugs 0.000 claims description 3
CVCQAQVBOPNTFI-AAONGDSNSA-N (3r,4r,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O CVCQAQVBOPNTFI-AAONGDSNSA-N 0.000 claims description 2
239000000839 emulsion Substances 0.000 claims description 2
239000000243 solution Substances 0.000 claims description 2
239000000725 suspension Substances 0.000 claims description 2
239000002253 acid Substances 0.000 claims 2
235000010376 calcium ascorbate Nutrition 0.000 claims 2
229940047036 calcium ascorbate Drugs 0.000 claims 2
239000011692 calcium ascorbate Substances 0.000 claims 2
BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 claims 2
RSYSVNVHLXTDIR-ZZMNMWMASA-L (2r)-2-[(1s)-1,2-dihydroxyethyl]-3-hydroxy-5-oxo-2h-furan-4-olate;manganese(2+) Chemical compound [Mn+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] RSYSVNVHLXTDIR-ZZMNMWMASA-L 0.000 claims 1
KWJPTZSGVFKSDH-UHFFFAOYSA-N 1-(3-nitrophenyl)piperazine;dihydrochloride Chemical compound Cl.Cl.[O-][N+](=O)C1=CC=CC(N2CCNCC2)=C1 KWJPTZSGVFKSDH-UHFFFAOYSA-N 0.000 claims 1
239000004260 Potassium ascorbate Substances 0.000 claims 1
229960001459 ferrous ascorbate Drugs 0.000 claims 1
235000019275 potassium ascorbate Nutrition 0.000 claims 1
229940017794 potassium ascorbate Drugs 0.000 claims 1
CONVKSGEGAVTMB-RXSVEWSESA-M potassium-L-ascorbate Chemical compound [K+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] CONVKSGEGAVTMB-RXSVEWSESA-M 0.000 claims 1
235000010378 sodium ascorbate Nutrition 0.000 claims 1
PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims 1
229960005055 sodium ascorbate Drugs 0.000 claims 1
PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims 1
210000000845 cartilage Anatomy 0.000 abstract description 24
230000022159 cartilage development Effects 0.000 abstract description 23
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 abstract description 14
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 abstract description 14
229960002442 glucosamine Drugs 0.000 abstract description 14
238000011282 treatment Methods 0.000 abstract description 14
230000001225 therapeutic effect Effects 0.000 abstract description 11
238000004519 manufacturing process Methods 0.000 abstract description 9
230000002195 synergetic effect Effects 0.000 abstract description 8
-1 ascorbic acid Chemical compound 0.000 abstract description 3
108010035532 Collagen Proteins 0.000 description 18
102000008186 Collagen Human genes 0.000 description 18
229920001436 collagen Polymers 0.000 description 18
210000002808 connective tissue Anatomy 0.000 description 17
206010039073 rheumatoid arthritis Diseases 0.000 description 12
NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 12
239000011686 zinc sulphate Substances 0.000 description 12
235000009529 zinc sulphate Nutrition 0.000 description 12
210000004027 cell Anatomy 0.000 description 11
230000000694 effects Effects 0.000 description 11
230000015572 biosynthetic process Effects 0.000 description 10
229920002683 Glycosaminoglycan Polymers 0.000 description 9
102000055008 Matrilin Proteins Human genes 0.000 description 8
108010072582 Matrilin Proteins Proteins 0.000 description 8
102000016611 Proteoglycans Human genes 0.000 description 8
108010067787 Proteoglycans Proteins 0.000 description 8
210000003321 cartilage cell Anatomy 0.000 description 8
239000001963 growth medium Substances 0.000 description 8
238000003786 synthesis reaction Methods 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
238000011161 development Methods 0.000 description 7
230000018109 developmental process Effects 0.000 description 7
238000004113 cell culture Methods 0.000 description 6
229920001287 Chondroitin sulfate Polymers 0.000 description 5
108010050808 Procollagen Proteins 0.000 description 5
231100000673 dose–response relationship Toxicity 0.000 description 5
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
241000124008 Mammalia Species 0.000 description 4
210000000988 bone and bone Anatomy 0.000 description 4
238000012360 testing method Methods 0.000 description 4
235000019154 vitamin C Nutrition 0.000 description 4
239000011718 vitamin C Substances 0.000 description 4
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
229920000288 Keratan sulfate Polymers 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
208000002193 Pain Diseases 0.000 description 3
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
229930003268 Vitamin C Natural products 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
210000001612 chondrocyte Anatomy 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
150000002016 disaccharides Chemical group 0.000 description 3
230000002708 enhancing effect Effects 0.000 description 3
150000002337 glycosamines Chemical class 0.000 description 3
229920002674 hyaluronan Polymers 0.000 description 3
229960003160 hyaluronic acid Drugs 0.000 description 3
230000033444 hydroxylation Effects 0.000 description 3
238000005805 hydroxylation reaction Methods 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
150000002500 ions Chemical class 0.000 description 3
KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 3
239000011591 potassium Chemical class 0.000 description 3
229910052700 potassium Inorganic materials 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
230000001737 promoting effect Effects 0.000 description 3
230000008439 repair process Effects 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
229910021653 sulphate ion Inorganic materials 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
239000011701 zinc Substances 0.000 description 3
229910052725 zinc Inorganic materials 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
229920002567 Chondroitin Polymers 0.000 description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 2
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
230000002917 arthritic effect Effects 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 2
230000002301 combined effect Effects 0.000 description 2
239000010949 copper Substances 0.000 description 2
229910052802 copper Inorganic materials 0.000 description 2
YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
229940050410 gluconate Drugs 0.000 description 2
QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 2
229960002591 hydroxyproline Drugs 0.000 description 2
229910052500 inorganic mineral Inorganic materials 0.000 description 2
230000007774 longterm Effects 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
239000000463 material Substances 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
235000010755 mineral Nutrition 0.000 description 2
239000011707 mineral Substances 0.000 description 2
238000001050 pharmacotherapy Methods 0.000 description 2
OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 2
229910052939 potassium sulfate Inorganic materials 0.000 description 2
239000001120 potassium sulphate Substances 0.000 description 2
235000011151 potassium sulphates Nutrition 0.000 description 2
239000002243 precursor Substances 0.000 description 2
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
230000008961 swelling Effects 0.000 description 2
239000011885 synergistic combination Substances 0.000 description 2
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
229940088594 vitamin Drugs 0.000 description 2
229930003231 vitamin Natural products 0.000 description 2
235000013343 vitamin Nutrition 0.000 description 2
239000011782 vitamin Substances 0.000 description 2
235000016804 zinc Nutrition 0.000 description 2
102000016284 Aggrecans Human genes 0.000 description 1
108010067219 Aggrecans Proteins 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
241000700198 Cavia Species 0.000 description 1
208000000094 Chronic Pain Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical class [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
241000283086 Equidae Species 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
208000004262 Food Hypersensitivity Diseases 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
206010060820 Joint injury Diseases 0.000 description 1
206010023230 Joint stiffness Diseases 0.000 description 1
206010023232 Joint swelling Diseases 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000023146 Pre-existing disease Diseases 0.000 description 1
241000219061 Rheum Species 0.000 description 1
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical class [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
229930003316 Vitamin D Natural products 0.000 description 1
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
230000009471 action Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
108010003059 aggrecanase Proteins 0.000 description 1
230000032683 aging Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
210000003423 ankle Anatomy 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
210000001188 articular cartilage Anatomy 0.000 description 1
230000008468 bone growth Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000003837 chick embryo Anatomy 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
239000011773 ferrous fumarate Substances 0.000 description 1
235000002332 ferrous fumarate Nutrition 0.000 description 1
229960000225 ferrous fumarate Drugs 0.000 description 1
239000004222 ferrous gluconate Substances 0.000 description 1
235000013924 ferrous gluconate Nutrition 0.000 description 1
229960001645 ferrous gluconate Drugs 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
108060002894 fibrillar collagen Proteins 0.000 description 1
102000013373 fibrillar collagen Human genes 0.000 description 1
235000020932 food allergy Nutrition 0.000 description 1
210000002683 foot Anatomy 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229940050411 fumarate Drugs 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
235000008216 herbs Nutrition 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
230000001788 irregular Effects 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
229910052747 lanthanoid Inorganic materials 0.000 description 1
150000002602 lanthanoids Chemical class 0.000 description 1
150000002605 large molecules Chemical class 0.000 description 1
210000000982 limb bud Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000009630 liquid culture Methods 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011572 manganese Substances 0.000 description 1
229910052748 manganese Inorganic materials 0.000 description 1
150000002696 manganese Chemical class 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000037353 metabolic pathway Effects 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
239000002417 nutraceutical Substances 0.000 description 1
235000021436 nutraceutical agent Nutrition 0.000 description 1
235000018343 nutrient deficiency Nutrition 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
244000052769 pathogen Species 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000004033 plastic Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
229910052761 rare earth metal Inorganic materials 0.000 description 1
150000002910 rare earth metals Chemical class 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000011669 selenium Chemical class 0.000 description 1
229910052711 selenium Chemical class 0.000 description 1
235000011649 selenium Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000035882 stress Effects 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000008354 tissue degradation Effects 0.000 description 1
229910052723 transition metal Inorganic materials 0.000 description 1
150000003624 transition metals Chemical class 0.000 description 1
239000011719 vitamin A Chemical class 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
235000019166 vitamin D Nutrition 0.000 description 1
239000011710 vitamin D Substances 0.000 description 1
150000003710 vitamin D derivatives Chemical class 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
229940046008 vitamin d Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Inorganic Chemistry (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA 2307079 2000-04-28 2000-04-28 Compositions utiles pour le traitement de maladies du tissu conjonctif Abandoned CA2307079A1 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA 2307079 CA2307079A1 (fr)	2000-04-28	2000-04-28	Compositions utiles pour le traitement de maladies du tissu conjonctif

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA 2307079 CA2307079A1 (fr)	2000-04-28	2000-04-28	Compositions utiles pour le traitement de maladies du tissu conjonctif

Publications (1)

Publication Number	Publication Date
CA2307079A1 true CA2307079A1 (fr)	2001-10-28

Family

ID=4166022

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2307079 Abandoned CA2307079A1 (fr)	2000-04-28	2000-04-28	Compositions utiles pour le traitement de maladies du tissu conjonctif

Country Status (1)

Country	Link
CA (1)	CA2307079A1 (fr)

2000
- 2000-04-28 CA CA 2307079 patent/CA2307079A1/fr not_active Abandoned

Legal Events

Date	Code	Title	Description
2002-08-01	FZDE	Dead

Publication	Publication Date	Title
EP1276485B1 (fr)	2006-08-02	Compositions utiles pour le traitement de pathologies des tissus conjonctifs
US6255295B1 (en)	2001-07-03	Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine composition for the protection, treatment, repair, and reduction of inflammation of connective tissue
US6271213B1 (en)	2001-08-07	Aminosugar, glycosaminoglycan, and S-adenosylmethionine composition for the treatment and repair of connective tissue
US6333304B1 (en)	2001-12-25	Therapeutic compositions containing glucosamine, collagen and a bioflavanol for repair and maintenance of connective tissue
CN104188999A (zh)	2014-12-10	一种具有增加骨密度、改善骨骼及关节功能的组合物及其制备方法
AU7822798A (en)	1999-12-20	Aminosugar, glycosaminoglycan, and s-adenosylmethionine composition for the treatment and repair of connective tissue
SG188936A1 (en)	2013-04-30	Sulfated unsaturated disaccharidic chondroitin sulfate in connective tissue protection and repair
EP1408988B1 (fr)	2007-06-13	Composition de supplements administrees par voie orale pour reparer le cartilage articulaire
AU767689B2 (en)	2003-11-20	Compositions based on chondroitin sulphate and chitosan for preventing or treating rheumatic disorders by general administration
CN106262809A (zh)	2017-01-04	一种增强骨密度缓解中老年关节疼痛的组合物
JP2001524080A (ja)	2001-11-27	関節炎の治療用加水分解コラーゲンタンパク質およびグルコサミンを含む組成物
CA2307079A1 (fr)	2001-10-28	Compositions utiles pour le traitement de maladies du tissu conjonctif
JP2011223965A (ja)	2011-11-10	コラーゲンを含む食品化合物
CA2607267A1 (fr)	2006-11-16	Alicament et preparation pharmaceutique pour le soulagement d'une maladie induite par un trouble metabolique au niveau du cartilage
JP2017025028A (ja)	2017-02-02	細胞外マトリックス分解抑制剤
HK1114774B (en)	2011-04-21	Compositions comprising an aminosugar, chondroitin, and s-adenosylmethionine
Petito	0	The Role of hyCURE® and Other Chondroprotective Agents in Oral Dietary Supplements
HK1065476B (en)	2008-01-25	Compositions of orally administered nutritional supplements to repair articular cartilage